July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Ataluren-mediated read-through of a nonsense mutation in FAM161A gene which causes retinitis pigmentosa
Author Affiliations & Notes
  • Avigail Beryozkin
    Ophthalmology, Hadassah Hebrew university, Jerusalem, Israel, Jerusalem, Israel
  • Ananya Samanta
    Inst. of Molecular Physiology, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Samer Khateb
    Ophthalmology, Hadassah Hebrew university, Jerusalem, Israel, Jerusalem, Israel
  • Eyal Banin
    Ophthalmology, Hadassah Hebrew university, Jerusalem, Israel, Jerusalem, Israel
  • Dror Sharon
    Ophthalmology, Hadassah Hebrew university, Jerusalem, Israel, Jerusalem, Israel
  • Uwe Wolfrum
    Inst. of Molecular Physiology, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Kerstin Nagel-Wolfrum
    Inst. of Molecular Physiology, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Footnotes
    Commercial Relationships   Avigail Beryozkin, None; Ananya Samanta, None; Samer Khateb, None; Eyal Banin, None; Dror Sharon, None; Uwe Wolfrum, None; Kerstin Nagel-Wolfrum, None
  • Footnotes
    Support  FFB PPA-0717-0719-RAD; FAUN-Stiftung
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5324. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Avigail Beryozkin, Ananya Samanta, Samer Khateb, Eyal Banin, Dror Sharon, Uwe Wolfrum, Kerstin Nagel-Wolfrum; Ataluren-mediated read-through of a nonsense mutation in FAM161A gene which causes retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5324. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : FAM161A mutations are currently the most common cause of autosomal recessive retinitis pigmentosa (ARRP) in the Israeli population. This gene is responsible for approximately 12% of all RP cases in Israeli Jewish patients, with only two mutations identified in this population. One of these mutations is a nonsense mutation (p.Arg523*) which results in a premature stop codon (PTC). Transitional read-through inducing drugs (TRIDs) suppress PTCs and thereby induce the re-expression of full-length proteins. Ataluren is one of the promising compounds for transitional read-through of nonsense mutations currently being used in clinical phase II trials for nonsense mutations in Aniridia. In this research, we investigate Ataluren as a potential treatment option for patients with the FAM161A nonsense mutation.

Methods : We generated fibroblast cell lines from 8 Israeli patients affected with ARRP due to the p.Arg523* nonsense mutation in FAM161A and age- matched healthy controls. FAM161A protein expression and localization was monitored in control, untreated and Ataluren-treated patient-derived fibroblasts by immunocytochemistry. Furthermore, primary ciliogenesis and cilia length was analyzed in starved control fibroblasts, patient-derived and Ataluren treated patient-derived fibroblasts by immunofluorescence analysis.

Results : We observed FAM161A expression in ciliated fibroblasts from healthy individuals located along cytoplasmic microtubules and in the Golgi apparatus. In patient-derived cells FAM161A expression was barely or not at all detectable after starvation. We detected defective ciliogenesis in patient-derived cells compared to healthy cells. However, Ataluren treatment of patient-derived cells restored FAM161A localization and furthermore restored ciliogenesis in the FAM161A p.Arg523* patient cells.

Conclusions : FAM161A is expressed in fibroblast cells along microtubules and the Golgi apparatus. In patient-derived cells, FAM161A localization and ciliogenesis can be restored after Ataluren treatment. These results emphasize the feasibility of Ataluren as a therapeutic strategy tackling RP caused by the FAM161A nonsense mutation.
Supports: FFB PPA-0717-0719-RAD (UW); FAUN-Stiftung (KNW)

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×